AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently Amended) A pyrimidone derivative represented by formula (I) or a salt thereof:

$$(X)_{m} \xrightarrow{N} \stackrel{N}{\underset{R}{\bigvee}} O$$

$$(Y)_{n} \xrightarrow{N} \stackrel{N}{\underset{R}{\bigvee}} O$$

wherein Q represents CH or nitrogen atom;

R represents a C₁-C₁₂ alkyl group;

the ring of:

 $\binom{N}{j}$

represents piperazine ring or piperidine ring;

each X independently represents

$$X^{1} - X^{2} -$$

wherein X¹ represents

an optionally partially hydrogenated $C_6\text{-}C_{10}$ aryl ring which may be substituted;

an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total;

```
a group represented by -N(Ra)(Rb)
      wherein Ra and Rb are the same or different and each is
      hydrogen,
      a C<sub>1</sub>-C<sub>4</sub> alkyl group,
      an aralkyl group which may be substituted, or
      an aryl group which may be substituted, or
      C<sub>1</sub>-C<sub>8</sub> alkylcarbonyl group;
X<sup>2</sup> represents
a bond,
a C<sub>1</sub>-C<sub>4</sub> alkylene group, or
N-Rd
      [[(]] wherein Rd represents
      a hydrogen atom,
      a C<sub>1</sub>-C<sub>4</sub> alkyl group, or
     C<sub>1</sub>-C<sub>8</sub> alkylcarbonyl group [[)]];
m represents an integer of 1 to 3;
each Y independently represents
         a hydroxy group, or
         a C<sub>1</sub>-C<sub>8</sub> alkyl group;
n represents an integer of 0 to 8;
               when the ring represented by X or X<sup>1</sup> has one or more substituents, the ring may have
one or more substituents selected from:
      a C_1-C_5 alkyl group;
```

```
C<sub>3</sub>-C<sub>6</sub> cycloalkyl group;
      a C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>1</sub>-C<sub>4</sub> alkyl group;
      a C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group;
      a halogen atom;
      a C<sub>1</sub>-C<sub>5</sub> halogenated alkyl group;
      cyano group;
      nitro group;
      formyl group;
      a benzene ring which may be substituted;
      a naphthalene ring which may be substituted;
      an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from oxygen
atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total;
      an amino group;
      dimethylamino group;
      an N-C<sub>3</sub>-C<sub>6</sub> cycloalkyl-N-C<sub>1</sub>-C<sub>4</sub> alkylaminoalkyl group wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may be
substituted by hydroxy group or C<sub>1</sub>-C<sub>4</sub> alkoxy group;
      a C<sub>1</sub>-C<sub>5</sub> monoalkylaminomethyl group;
      a C<sub>2</sub>-C<sub>10</sub> dialkylaminomethyl group;
      pyrrolidinylmethyl group;
      piperidinylmethyl group;
      morpholinomethyl group;
      piperazinylmethyl group;
     pyrrolylmethyl group;
```

```
imidazolylmethyl group;
      pyrazolylmethyl group;
      triazolylmethyl group;
      and a group of the formula -E-Rf wherein
           E represents O, S, SO, SO<sub>2</sub>, CO or N(R<sup>4</sup>) and
            Rf represents
                  a C<sub>1</sub>-C<sub>5</sub> alkyl group,
                  a C<sub>4</sub>-C<sub>7</sub> cycloalkyl group,
                  a C<sub>4</sub>-C<sub>7</sub> cycloalkylalkl group,
                  a C<sub>1</sub>-C<sub>5</sub> hydroxyalkyl group,
                  a benzene ring which may be substituted,
                  a naphthalene ring which may be substituted,
                  an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from
oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total,
                  an N-C<sub>3</sub>-C<sub>6</sub> cycloalkyl-N-C<sub>1</sub>-C<sub>4</sub> alkylaminoalkyl group,
                  a C<sub>1</sub>-C<sub>5</sub> monoalkylaminoalkyl group,
                  C<sub>2</sub>-C<sub>10</sub> dialkylaminoalkyl group,
                 pyrrolidinylmethyl group,
                 piperidinylmethyl group,
                 morpholinomethyl group,
                 piperazinylmethyl group,
                 pyrrolylmethyl group,
                 imidazolylmethyl group,
```

pyrazolylmethyl group or

triazolylmethyl group,

C₁-C₈ alkylcarbonyl group,

C₃-C₈ cycloalkylcarbonyl group which may be substituted,

aralkycarbonyl group which may be substituted,

C₆-C₁₀ arylcarbonyl group which may be substituted,

C₁-C₈ alkysulfonyl group,

C₃-C₈ cycloalkylsulfonyl group which may be substituted,

aralkysulfonyl group which may be substituted,

C₆-C₁₀ arylsulfonyl group which may be substituted,

C₁-C₈ alkyloxycarbonyl group,

C₃-C₈ cycloalkyloxycarbonyl group which may be substituted,

aralkyoxycarbonyl group which may be substituted,

C₆-C₁₀ aryloxycarbonyl group which may be substituted,

aminocarbonyl,

N-C₁-C₈ alkylaminocarbonyl group,

N, N'-C1-C8 dialkylaminocarbonyl group,

N-C₁-C₈ alkyl-N'-C₃-C₈ cycloalkylaminocarbonyl group,

N-C₁-C₈ alkyl-N'-aralkylaminocarbonyl group,

N-C₁-C₈ alkyl-N'-C₆-C₁₀ arylaminocarbonyl group,

C₃-C₈ cycloalkylaminocarbonyl group,

N,N'-C3-C8 dicycloalkylaminoycarbonyl group,

N-C₃-C₈ cycloalkyl-N'-aralkylaminocarbonyl group,

```
N-C<sub>3</sub>-C<sub>8</sub> cycloalkyl-N'-C<sub>6</sub>-C<sub>10</sub> arylaminocarbonyl group, aralkylaminocarbonyl group,
```

N,N'-diaralkylaminocarbonyl group,

N-aralkyl- N'-C₆-C₁₀ arylaminocarbonyl group,

C₆-C₁₀ arylaminocarbonyl group,

N,N'-C₆-C₁₀ diarylaminocarbonyl group, and

R⁴ represents

a hydrogen atom,

a C₁-C₄ alkyl group,

an aralkyl group,

C₃-C₈ cycloalkyl group or

an aryl group which may be substituted; and

when the ring represented by X, or X^1 has one or more substituents, the substituent may further have one or more substituents selected from:

```
a C<sub>1</sub>-C<sub>5</sub> alkyl group;
```

C₃-C₆ cycloalkyl group;

a C₃-C₆ cycloalkyloxy group;

C₁-C₄ hydroxyalkyl group;

a C₁-C₅ alkoxy group;

a C₄-C₇ cycloalkylalkoxy group;

a C₁-C₅ alkylthio group;

a C₁-C₅ alkylsulfonyl group;

a halogen atom;

```
a C<sub>1</sub>-C<sub>5</sub> halogenated alkyl group;
a C<sub>1</sub>-C<sub>5</sub> halogenated alkoxy group;
hydroxyl group;
cyano group;
nitro group;
formyl group;
a C<sub>2</sub>-C<sub>6</sub> alkylcarbonyl group;
amino group;
a C<sub>1</sub>-C<sub>5</sub> monoalkylamino group;
a C<sub>2</sub>-C<sub>10</sub> dialkylamino group;
a cyclic amino group;
a C<sub>2</sub>-C<sub>10</sub> monoalkylaminomethyl group;
a C<sub>3</sub>-C<sub>11</sub> dialkylaminomethyl group;
a phenyl group;
an aralkyloxy group;
an aralkyloxycarbonyl group;
an C<sub>2</sub>-C<sub>4</sub> alkanoyloxy-C<sub>1</sub>-C<sub>4</sub> alkyl group;
an alkanoylamino group;
N-C<sub>1</sub>-C<sub>4</sub> alkyl-N-alkanoylamino;
N-C<sub>1</sub>-C<sub>4</sub> alkyl-N-heterocyclic ring amino group; and
a diheterocyclic ring amino group.
```

2. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 1 having the following formula(II)

$$(X)_{p} \longrightarrow (Y)_{r}$$

$$(X)_{q} \longrightarrow (Y)_{r}$$

$$(X)_{q} \longrightarrow (Y)_{r}$$

$$(X)_{q} \longrightarrow (Y)_{r}$$

$$(X)_{q} \longrightarrow (Y)_{r}$$

wherein Q, R, X and Y are the same as those defined in claim 1; p is 0 or 1; q is 0 or 1; r is an integer of 0 to 6; p+q is 1 or 2; and Z represents N or CZ^1 wherein Z^1 represents hydrogen atom or Y.

- 3. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim2, wherein R is a C₁-C₃ alkyl group.
- 4. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 3, wherein R is methyl group or ethyl group; Y is in 3-, 4- or 5-position of the piperazine ring or the piperidine ring; p+q is 1; and r is an integer of 0 to 3.
- 5. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 4, wherein X is a C_1 - C_8 alkyl group which may be substituted or a C_6 - C_{10} aryl ring which may be substituted; Y is a C_1 - C_6 alkyl group; p is 1; q is 0; r is an integer of 0 to 3; and Z is N or CH.
- 6. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 5, wherein X is a benzene ring which may be substituted, a benzyl group which may be substituted; Y is a methyl group; Z is N and r is 0 or 1.

one;

- 7. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 4, wherein X is a benzene ring which may be substituted, or a benzyl group which may be substituted; Y is a methyl group which may be substituted; Z is N and p is 0.
- 8. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 4, wherein X is a C_1 - C_8 alkyl group substituted by a benzene ring which may be substituted or a benzene ring which may be substituted; Y is a hydroxy group; Z is CH or C-Y and r is 0 or 1.
- 9. (Previously Presented) The pyrimidone derivative or the salt thereof according to claim 8, wherein X is a benzyl group which may be substituted or a benzene ring which may be substituted; Y is a hydroxy group; Z is CH or C-Y and r is 0 or 1.
- 10. (Original) A pyrimidone derivative which is selected from the group consisting of: 2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; (*S*)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; (*S*)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-
- (*R*)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one:
- 2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;

- 2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(3-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluoro-3-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (S)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (*R*)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;

- 2-(3-(4-Fluoro-2-methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Fluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Bromo-4-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Chloro-6-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,4-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,6-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one:
- 2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-

4-one;

- 2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;(1034)
- 2-(3-(5-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (S)-2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one;
- 2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one;

- 2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Benzylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Benzoylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Methyl-3-phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (*S*)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (*R*)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-

- 3*H*-pyrimidin-4-one;
- 2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-Benzyl-3-(ethoxycarbonyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(4-methyl-3-(1-naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(5,5-Dimethyl-3-(2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-Phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Chlorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Bromophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- $2-(3-(4-((Pyrrolidin-1-yl)methyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3\mathit{H-1}-((Pyrrolidin-1-yl)methyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)-3-methyl-6-(4-pyridyl)-3\mathit{H-2}-((Pyrrolidin-1-yl)methyl)-3-methyl-6-(4-pyridyl)-3-methyl-6-(4-pyri$
- pyrimidin-4-one;
- (*S*)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- (R)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-

- 3*H*-pyrimidin-4-one;
- 2-(3-Hydroxy-3-phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-

one;

2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-

one;

2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-

one;

- 2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-

4-one:

2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-

4-one;

2-(3-(2-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-

4-one;

- 2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(6-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (*S*)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (*R*)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3*H*-pyrimidin-4-one;
- 2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;

- 2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-

```
pyrimidin-4-one;
```

- 2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (*S*)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (*R*)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- $2\hbox{-}(4\hbox{-}(4\hbox{-}Fluorophenyl)piperidin-1-yl)-3-methyl-6\hbox{-}(4\hbox{-}pyrimidyl)-3\textit{H-}pyrimidin-4-one;}$
- $2\hbox{-}(4\hbox{-}Cyano\hbox{-}4\hbox{-}phenylpiperidin-}1\hbox{-}yl)\hbox{-}3\hbox{-}methyl\hbox{-}6\hbox{-}(4\hbox{-}pyrimidyl)\hbox{-}3$$H$-pyrimidin-}4\hbox{-}one;$
- 2-(4-(6-Fluorobenofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;

- 2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (S)-2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- (*R*)-2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(3-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(4-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one;
- 2-(4-(5-Methylbenzofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one; and
- 2-(4-(6-Fluorobenzothiophene-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3*H*-pyrimidin-4-one

or a salt thereof, or a solvate thereof or a hydrate thereof.

- 11. (Previously Presented) A medicament composition comprising as an active ingredient at least one pyrimidone derivative represented by formula (I) or a salt thereof according to claim 1.
 - 12. (Canceled)
- 13. (Currently Amended) A method for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity selected from Alzheimer disease and non-insulin dependent diabetes comprising administering to a patient an a therapeutically effective amount of the composition according to claim 11 to inhibit activity of tau protein kinase 1.

- 14. (Currently Amended) A method for preventive and/or therapeutic treatment of a neurodegenerative disease comprising administering to a patient a preventively and/or therapeutically effective amount of the composition according to claim 11, wherein the neurodegenerative disease is selected from Alzheimer disease, ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies, and glaucoma.
 - 15. (Canceled)
- 16. (Currently Amended) A method for preventive and/or therapeutic treatment of a disease selected from non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, and alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and a virus-induced tumor comprising administering to a patient a preventively and/or therapeutically effective amount of the composition according to claim 11.